Literature DB >> 16996280

Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T.

Sumita Adhya1, Glyn Johnson, Joseph Herbert, Hina Jaggi, James S Babb, Robert I Grossman, Matilde Inglese.   

Abstract

This study aimed to determine regional pattern of tissue perfusion in the normal-appearing white matter (NAWM) of patients with primary-progressive (PP), relapsing-remitting (RR) multiple sclerosis (MS) and healthy controls, and to investigate the association between perfusion abnormalities and clinical disability. Using dynamic susceptibility contrast (DSC) perfusion MRI at 3 T, we studied 22 patients with clinically definite MS, 11 with PP-MS and 11 with RR-MS and 11 age- and gender-matched healthy volunteers. The MRI protocol included axial dual-echo, dynamic susceptibility contrast enhanced (DSC) T2*-weighted and post-contrast T1-weighted images. Absolute cerebral blood flow (CBF), cerebral blood volume (CBV) and mean transit time (MTT) were measured in the periventricular, frontal, occipital NAWM and in the splenium of the corpus callosum. Compared to controls, CBF and CBV were significantly lower in all NAWM regions in both PP-MS patients (p values from <0.0001 to 0.001) and RR-MS (p values from <0.0001 to 0.020). Compared to RR-MS, PP-MS patients showed significantly lower CBF in the periventricular NAWM (p=0.002) and lower CBV in the periventricular and frontal NAWM (p values: 0.0029 and 0.022). EDSS was significantly correlated with the periventricular CBF (r=-0.48, p=0.0016) and with the periventricular and frontal CBV (r=-0.42, p=0.015; r=-0.35, p=0.038, respectively). This study suggests that the hemodynamic abnormalities of NAWM have clinical relevance in patients with MS. DSC perfusion MRI might provide a relevant objective measure of disease activity and treatment efficacy.

Entities:  

Mesh:

Year:  2006        PMID: 16996280      PMCID: PMC1752216          DOI: 10.1016/j.neuroimage.2006.08.008

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  41 in total

1.  Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition.

Authors:  F Calamante; D G Gadian; A Connelly
Journal:  Magn Reson Med       Date:  2000-09       Impact factor: 4.668

2.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study.

Authors:  Stephan G Wetzel; Soonmee Cha; Glyn Johnson; Peter Lee; Meng Law; David L Kasow; Sean D Pierce; Xiaonan Xue
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

3.  Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose.

Authors:  Christoph Manka; Frank Träber; Juergen Gieseke; Hans H Schild; Christiane K Kuhl
Journal:  Radiology       Date:  2005-01-21       Impact factor: 11.105

4.  Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.

Authors:  Nathan A Johnson; Geon-Ho Jahng; Michael W Weiner; Bruce L Miller; Helena C Chui; William J Jagust; Maria L Gorno-Tempini; Norbert Schuff
Journal:  Radiology       Date:  2005-03       Impact factor: 11.105

Review 5.  The pathology of primary progressive multiple sclerosis.

Authors:  W Brück; C Lucchinetti; H Lassmann
Journal:  Mult Scler       Date:  2002-04       Impact factor: 6.312

6.  Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex.

Authors:  L Chang; T Ernst; M Leonido-Yee; O Speck
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

7.  Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction.

Authors:  R Haselhorst; L Kappos; D Bilecen; K Scheffler; D Möri; E W Radü; J Seelig
Journal:  J Magn Reson Imaging       Date:  2000-05       Impact factor: 4.813

8.  Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis.

Authors:  N Evangelou; D Konz; M M Esiri; S Smith; J Palace; P M Matthews
Journal:  Brain       Date:  2000-09       Impact factor: 13.501

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Is inflammation important in early PPMS? a longitudinal MRI study.

Authors:  G T Ingle; J Sastre-Garriga; D H Miller; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

View more
  57 in total

Review 1.  Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.

Authors:  Christian Enzinger; Frederik Barkhof; Olga Ciccarelli; Massimo Filippi; Ludwig Kappos; Maria A Rocca; Stefan Ropele; Àlex Rovira; Torben Schneider; Nicola de Stefano; Hugo Vrenken; Claudia Wheeler-Kingshott; Jens Wuerfel; Franz Fazekas
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

Review 2.  CCSVI and MS: no meaning, no fact.

Authors:  Claudio Baracchini; Matteo Atzori; Paolo Gallo
Journal:  Neurol Sci       Date:  2012-05-09       Impact factor: 3.307

3.  Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability.

Authors:  David Paling; Esben Thade Petersen; Daniel J Tozer; Daniel R Altmann; Claudia A M Wheeler-Kingshott; Raju Kapoor; David H Miller; Xavier Golay
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-18       Impact factor: 6.200

4.  Multiple sclerosis and chronic cerebrospinal venous insufficiency: the neuroimaging perspective.

Authors:  M Filippi; M A Rocca; F Barkhof; R Bakshi; F Fazekas; O Khan; D Pelletier; A Rovira; J Simon
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-03       Impact factor: 3.825

5.  Veins in plaques of multiple sclerosis patients - a longitudinal magnetic resonance imaging study at 7 Tesla.

Authors:  Assunta Dal-Bianco; Simon Hametner; Günther Grabner; Melanie Schernthaner; Claudia Kronnerwetter; Andreas Reitner; Clemens Vass; Karl Kircher; Eduard Auff; Fritz Leutmezer; Karl Vass; Siegfried Trattnig
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

6.  Brain perfusion by arterial spin labeling MRI in multiple sclerosis.

Authors:  Tatiana Koudriavtseva; Domenico Plantone; Rosaria Renna; Matilde Inglese
Journal:  J Neurol       Date:  2015-05-28       Impact factor: 4.849

7.  Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis.

Authors:  Matilde Inglese; Sumita Adhya; Glyn Johnson; James S Babb; Laura Miles; Hina Jaggi; Joseph Herbert; Robert I Grossman
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-02       Impact factor: 6.200

8.  Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study.

Authors:  Denis Peruzzo; Marco Castellaro; Massimiliano Calabrese; Elisa Veronese; Francesca Rinaldi; Valentina Bernardi; Alice Favaretto; Paolo Gallo; Alessandra Bertoldo
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

Review 9.  MRI in multiple sclerosis: current status and future prospects.

Authors:  Rohit Bakshi; Alan J Thompson; Maria A Rocca; Daniel Pelletier; Vincent Dousset; Frederik Barkhof; Matilde Inglese; Charles R G Guttmann; Mark A Horsfield; Massimo Filippi
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

10.  White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis.

Authors:  Andrew W Varga; Glyn Johnson; James S Babb; Joseph Herbert; Robert I Grossman; Matilde Inglese
Journal:  J Neurol Sci       Date:  2009-01-31       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.